ENTITY

Canbas Co Ltd (4575 JP)

7
Analysis
Health Care • Japan
CanBas Company Ltd. is a biopharmaceutical company that develops anti-cancer drugs with fewer side effects. The Company's core technologies include drugs that target the G2 checkpoint and a screening system to find selective abrogators of the G2 checkpoint.
more
bullish•Canbas Co Ltd
•13 Aug 2026 11:00•Issuer-paid

Canbas Co Ltd (4575 JP): Full-year FY06/26 flash update

CanBas reported no operating revenue in FY06/26, with an operating loss of JPY1.4bn and a net loss of JPY1.3bn. R&D expenses increased by...

Logo
100 Views
Share
bullish•Canbas Co Ltd
•15 May 2026 11:00•Issuer-paid

Canbas Co Ltd (4575 JP): Cumulative Q3 FY06/26 flash update

CanBas reported no operating revenue in cumulative Q3 FY06/25, with an operating loss of JPY916mn and net loss of JPY874mn. R&D expenses...

Logo
94 Views
Share
bullish•Canbas Co Ltd
•16 Feb 2026 13:00•Issuer-paid

Canbas Co Ltd (4575 JP): 1H FY06/26 report update

CanBas reported no operating revenue in 1H FY06/26, with operating expenses at JPY600mn, primarily from R&D. Total assets decreased JPY577mn...

Logo
194 Views
Share
bullish•Canbas Co Ltd
•12 Nov 2025 14:00•Issuer-paid

Canbas Co Ltd (4575 JP): Q1 FY 06/26 flash update

CanBas reported no operating revenue in Q1 FY06/26, with an operating loss of JPY360mn and net loss of JPY349mn. R&D expenses increased by...

Logo
183 Views
Share
bullish•Canbas Co Ltd
•14 May 2025 08:00•Issuer-paid

Canbas Co Ltd (4575 JP): Q3 FY06/25 flash update

Operating revenue was zero in cumulative Q3 FY06/24; operating loss was JPY799mn, and net loss JPY832mn. R&D expenses increased 70.8% YoY to...

Logo
244 Views
Share
x